Domestic companies’ strategy to avoid ‘Pradaxa’ patent
Domestic pharmaceutical companies are altering strategies on patent suits to develop generics of ‘Pradaxa(generic name: dabigatran).’
As keeping losing on its substance and composition patent nullification trials, they are changing their way to avoid them instead of nullifying them.
Recently, S...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
